Chronic inducible urticaria (CIU) represents a significant dermatological syndrome characterized by frequent hives triggered by non-allergic stimuli. The global market for CIU therapies is projected to experience rapid growth over the next few years, driven by factors such as increasing prevalence of CIU, enhanced diagnostic capabilities, and advan